CBG and Neuroprotection: What the Latest Research Reveals About the "Mother Cannabinoid"

Cannabigerol (CBG) is often called the "mother cannabinoid" because it is the biosynthetic precursor from which most other cannabinoids — including THC and CBD — are derived. As the cannabis plant matures, CBGA (the acidic form of CBG) is converted by enzymes into THCA, CBDA, and CBCA. By the time most cannabis plants reach harvest, CBG concentrations are typically below 1% of total cannabinoid content.

This scarcity has historically limited CBG research. But advances in selective breeding and extraction technology have made CBG-rich cultivars and standardized CBG extracts commercially viable, enabling a new wave of research into CBG's therapeutic properties.

Neuroprotective Effects

The most compelling emerging evidence for CBG concerns its neuroprotective properties. A 2024 study published in Neurochemistry International found that CBG significantly reduced neuroinflammation and oxidative stress in a mouse model of Huntington's disease, outperforming CBD in several key measures. The researchers identified CBG's activity at PPARγ receptors — which regulate inflammation and cell survival — as a likely mechanism.

Earlier research had demonstrated CBG's neuroprotective effects in models of Parkinson's disease and ALS. A 2023 study found that CBG reduced dopaminergic neuron loss in a 6-OHDA mouse model of Parkinson's by 40% compared to vehicle controls. These findings are preliminary — mouse models do not always translate to human outcomes — but the consistency across multiple neurodegenerative disease models is notable.

Anti-Inflammatory Properties

CBG has demonstrated potent anti-inflammatory activity in multiple preclinical models. Its primary anti-inflammatory mechanism appears to involve inhibition of the COX-2 enzyme (the same target as NSAIDs like ibuprofen) and modulation of the NF-κB inflammatory signaling pathway. A 2024 study found CBG to be more potent than CBD as a COX-2 inhibitor in vitro.

Antibacterial Activity

One of the most surprising findings in CBG research is its antibacterial activity against methicillin-resistant Staphylococcus aureus (MRSA). A 2020 study published in ACS Infectious Diseases found CBG to be highly effective against MRSA biofilms — a particularly difficult-to-treat form of bacterial infection — at concentrations achievable with topical application. This finding has generated significant interest in CBG-based topical formulations for wound care.

Consumer Implications

For consumers, the key takeaway is that CBG is not a marketing term — it has a distinct pharmacological profile from CBD and THC, with emerging evidence for specific therapeutic applications. Products with standardized, therapeutically meaningful CBG concentrations (not trace amounts) are the only ones likely to produce the effects documented in research.